Skip to main content

Drug Interactions between Benlysta and ixazomib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

belimumab ixazomib

Applies to: Benlysta (belimumab) and ixazomib

MONITOR: Concomitant use of belimumab and biologic therapies, including B-cell targeted therapies with immunosuppressant effects may lead to an increase in the rate of severe adverse events and serious infections. In a double-blind, randomized, placebo-controlled, phase 3 trial in adults with systemic lupus erythematosus (SLE) receiving belimumab, the addition of rituximab was associated with serious adverse events in 22.2% and serious infections in 9% of patients, compared to 13.9% and 2.8% of patients, respectively, in the placebo add-on group. Clinical data for other B-cell targeted therapies are unavailable.

MANAGEMENT: According to the manufacturer of belimumab, available data do not support the coadministration of belimumab with rituximab in patients with SLE. Caution and monitoring for adverse reactions, particularly infections, is advised if concomitant use of belimumab with other biologic therapies with immunosuppressant effects, particularly B-cell targeted therapies including but not limited to ocrelizumab, ofatumumab, or obinutuzumab. Some authorities advise against their concomitant use.

References (4)
  1. (2023) "Product Information. Benlysta (belimumab)." GlaxoSmithKline, SUPPL-79
  2. (2023) "Product Information. Benlysta (belimumab)." GlaxoSmithKline Australia Pty Ltd, 16.0
  3. (2023) "Product Information. Benlysta (belimumab)." GlaxoSmithKline UK Ltd
  4. (2024) "Product Information. Benlysta (belimumab)." GlaxoSmithKline Inc, 279901

Drug and food interactions

Moderate

ixazomib food

Applies to: ixazomib

ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of ixazomib. A food effect study found that administration of a single 4 mg dose of ixazomib with a high-fat meal decreased ixazomib peak plasma concentration (Cmax) by 69% and systemic exposure (AUC) by 28%.

MANAGEMENT: Ixazomib should be taken at least one hour before or two hours after eating. On days when both ixazomib and dexamethasone are administered, advise patients to separate dosing times, since dexamethasone should be taken with food while ixazomib should be taken on an empty stomach.

References (1)
  1. (2015) "Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer